Table 2.
CSF Biomarker Data
| Mean (SD)
|
|||
|---|---|---|---|
| E/C/ALA (n = 24) | CoQ (n = 20) | Placebo (n = 22) | |
| A342 level at baseline, pg/mL | 190 (43) | 185 (54) | 201 (57) |
| A342 level change | −8 (23) | −15 (31) | −6 (37) |
| Tau level at baseline, pg/mL | 123 (60) | 109 (64) | 114 (84) |
| Tau level change | −23 (39) | −9 (21) | −12 (19) |
| P-tau181 level at baseline, pg/mL | 68 (33) | 70 (37) | 58 (35) |
| P-tau181 level change | −6 (19) | −4 (17) | 0.5 (19) |
| F2-isoprostane level at baseline, pg/mL | 38 (15) | 34 (15) | 35 (12) |
| F2-isoprostane level change | −7 (10)a | 0 (8) | 0 (6) |
Abbreviations: CoQ, coenzyme Q; CSF, cerebrospinal fluid; E/C/ALA, vitamin E plus vitamin C plus α-lipoic acid.
a
P = .04, analysis of covariance, adjusted for multiple comparisons.